Impact BioMedical Inc. (IBO) Fair Value 2026

IBO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.4 /10

32 fundamental signals · 3 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-28, Impact BioMedical Inc. (IBO) trades at $0.44, versus a $0.01 median fair value across its 3 active models — 97.7% below the current price. QOC: 4.4/10. Value Trap Risk: 42/100 (WARN). 3/13 models active.

Key Facts

Ticker
IBO
Price
$0.44
Quality Score
4.4/10
Value Trap Risk
42/100
Models Active
3/13
Last Updated
Strength: 3 independent models provide multi-angle coverage
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

Is Impact BioMedical Inc. (IBO) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Impact BioMedical Inc. (IBO) appears overvalued as of : the median of 3 independent fair value estimates is $0.01, 97.7% below the current price of $0.44. Estimates range from $0.01 to $0.04. IBO scores 4.4/10 on fundamental quality and 42/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. IBO’s -97.7% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Impact BioMedical Inc. Stock in 2026? →

What Fair Value Does Each Model Give IBO?

3 Intrinsic Value Models vs. Current Price ($0.44)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.04 -91.0%
Relative · Medium Conviction
 $0.01 -97.7%
Option-Based · Low Conviction
 $0.01 -98.1%

All Models Active

All 3 models are displayed above.

What Is IBO's Fair Value Range?

Spread across 3 independent models · $0.01 to $0.04

CirclFi's 3 active models place Impact BioMedical Inc. (IBO) between $0.01 and $0.04 per share, a spread of 315% of the median. The median of that range — $0.01 — is the fair value CirclFi publishes for IBO, against a current price of $0.44.

Low · PWERMHigh · ML-RIV
$0.01median $0.01$0.04
Where the range comes from
Most bearish modelPWERM$0.01
Most bullish modelML Residual Income$0.04
Model agreement0 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for IBO. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on IBO, not a CirclFi price target. How each model works →

What Is Impact BioMedical Inc. (IBO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Impact BioMedical Inc.'s intrinsic value is estimated at $0.01. Trading at its current price of $0.44, the valuation engine raises significant caution: 3 of 3 models flag downside risk, projecting a median implied return of -97.7%.

What Do the Models Say About IBO?

3 of 13 models are currently active for IBO. All 3 active models suggest the stock trades above fair value. Taken together, their median fair value for IBO is $0.01 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does IBO Rank in Biotechnology?

Among 625 Biotechnology stocks, IBO ranks #478 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Impact BioMedical Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including breakthrough therapy designations — shape both the opportunity set and risk profile.

Is IBO a Value Trap?

CirclFi's Value Trap algorithm assigns IBO a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Impact BioMedical Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Impact BioMedical Inc. scores 4.4 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

Models cluster within a tight range (+7.1% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IBO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across IBO's 3 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Impact BioMedical Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

COCPCocrystal Pharma, Inc.QOC 4.4PHIOPhio Pharmaceuticals Corp.QOC 4.4TNYATenaya Therapeutics, Inc.QOC 4.4IKTInhibikase Therapeutics, Inc.QOC 4.4GPCRStructure Therapeutics Inc.QOC 4.4BYSIBeyondSpring Inc.QOC 4.3CRMDCorMedix Inc.QOC 9.0CELZCreative Medical Technology Holdings, Inc.QOC 5.9ABVCABVC BioPharma, Inc.QOC 5.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: COCP · PHIO · TNYA · IKT · GPCR · BYSI · CRMD · CELZ · ABVC · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to IBO?

7 companies across all industries closest to IBO’s Quality of Company score of 4.4/10.

SHFSSHF Holdings, Inc.QOC 4.4EVOHEvoAir Holdings Inc.QOC 4.4BFNHBioForce Nanosciences Holdings, Inc.QOC 4.4KOANResonate Blends, Inc.QOC 4.4NOTEFiscalNote Holdings, Inc.QOC 4.4KBLBKraig Biocraft Laboratories, Inc.QOC 4.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SHFS · EVOH · BFNH · KOAN · NOTE · KBLB · NVDA

Where Does IBO Sit in CirclFi's Biotechnology Rankings?

IBO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Impact BioMedical Inc.’s Valuation?

What is Impact BioMedical Inc.'s intrinsic value in 2026?

CirclFi puts Impact BioMedical Inc. (IBO)'s intrinsic value at $0.01 — the median of 3 independent model estimates as of 2026-08-28, ranging from $0.01 to $0.04. The Quality of Company score is 4.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IBO overvalued or undervalued right now?

At $0.44, 0 of 3 active models suggest IBO may be undervalued, while 3 indicate potential overvaluation. The median of all 3 fair value estimates is $0.01, 97.7% below the current price of $0.44 — a consensus view that IBO is overvalued. The assessment depends on which methodology best fits Impact BioMedical Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.4 mean for IBO?

Impact BioMedical Inc.'s QOC of 4.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on IBO?

CirclFi analyzes IBO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on IBO?

Of the 3 models currently active on IBO, ML Residual Income is the most bullish at $0.04 per share, and PWERM is the most bearish at $0.01. CirclFi's published fair value for IBO is the median of that range, $0.01, not either extreme. The gap between the two ends equals 315% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is IBO a value trap in 2026?

Impact BioMedical Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Impact BioMedical Inc. (IBO) has a median fair value of $0.01 — 97.7% below the current price of $0.44 — as of 2026-08-28.” Source: circlfi.com/stock/IBO/ · Methodology
Primary sources for this IBO valuation
  • Financial statements: Impact BioMedical Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001834105) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for IBO as of ; valuations recomputed .